Chuanda Zhu
Chuanda Zhu has a total of 63 co-authors. Here are the top co-authors by number of shared publications:
- Zhiqiang Lin
Institute of Systems Biomedicine, School of Basic Medical Sciences, Department of Pathology, Beijing Key Laboratory of Tumor Systems Biology Peking University Health Science Center Beijing China
6 shared publications - Ling Liang
Peking University, Beijing, China
4 shared publications - Lidong Gong
Institute of Systems Biomedicine, School of Basic Medical Sciences
3 shared publications Ao Yang
Department of Biophysics, State Key Laboratory of Natural and Biomimetic Drugs, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, China
2 shared publicationsLijun Zhong
Center of Medical and Health Analysis, Peking University Health Science Center, Beijing, China
2 shared publicationsLu Qin
Department of Biophysics, State Key Laboratory of Natural and Biomimetic Drugs, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, China
2 shared publications
Latest Publications
- Open Access
- 2 November 2026
- Published by Wiley in Small Structures
- Vol. 7 (11)
Injectable Zn 2+ ‐Alginate Hydrogel Delivering NT3 for Anti‐Inflammatory and Neuroregenerative Therapy in Spinal Cord Injury
Utilizing hydrogels to remodel the adaptive microenvironment provides an effective strategy for mitigating chronic inflammation in spinal cord injury (SCI) repair. However, the persistent detrimental impact of inflammation on SCI remains a critical issue requiring urgent resolution. This study developed an in situ cross‐linked alginate hydrogel stabilized by Zn 2+ coordination, functionalized with His‐tagged NT3 to enable anti‐inflammatory modulation and neural regeneration following SCI. The hydrogel consists of sodium alginate, zinc sulfate (a Zn 2+ source), and His‐NT3 (a neurotrophic factor). Within this system, sodium alginate forms reversible metal–ligand coordination bonds with Zn 2+ , while the His‐NT3 protein is integrated via affinity‐based interactions, contributing to localized retention and sustained therapeutic delivery. Experimental results demonstrate that this alginate‐based injectable hydrogel effectively modulates immune responses, promotes axonal regeneration, and concurrently enhances neurotransmitter‐associated synaptogenesis and remyelination. Furthermore, significant improvements were observed in the recovery of neurological functions, including motor function, sensory function, and bladder function. Collectively, these results demonstrate the promising potential of this alginate‐based injectable hydrogel for the treatment of traumatic SCI.
- 2 November 2026
- Published by Wiley in Small Structures
- Vol. 7 (11)
Open AccessInjectable Zn 2+ ‐Alginate Hydrogel Delivering NT3 for Anti‐Inflammatory and Neuroregenerative Therapy in Spinal Cord Injury
Utilizing hydrogels to remodel the adaptive microenvironment provides an effective strategy for mitigating chronic inflammation in spinal cord injury (SCI) repair. However, the persistent detrimental impact of inflammation on SCI remains a critical issue requiring urgent resolution. This study developed an in situ cross‐linked alginate hydrogel stabilized by Zn 2+ coordination, functionalized with His‐tagged NT3 to enable anti‐inflammatory modulation and neural regeneration following SCI. The hydrogel consists of sodium alginate, zinc sulfate (a Zn 2+ source), and His‐NT3 (a neurotrophic factor). Within this system, sodium alginate forms reversible metal–ligand coordination bonds with Zn 2+ , while the His‐NT3 protein is integrated via affinity‐based interactions, contributing to localized retention and sustained therapeutic delivery. Experimental results demonstrate that this alginate‐based injectable hydrogel effectively modulates immune responses, promotes axonal regeneration, and concurrently enhances neurotransmitter‐associated synaptogenesis and remyelination. Furthermore, significant improvements were observed in the recovery of neurological functions, including motor function, sensory function, and bladder function. Collectively, these results demonstrate the promising potential of this alginate‐based injectable hydrogel for the treatment of traumatic SCI.
- Open Access
- 11 June 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 5214
Author Correction: Structural dynamics of the midnolin-proteasome during ubiquitin-independent substrate turnover
- 11 June 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 5214
Open AccessAuthor Correction: Structural dynamics of the midnolin-proteasome during ubiquitin-independent substrate turnover
- Open Access
- 27 March 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 2800
Structural dynamics of the midnolin-proteasome during ubiquitin-independent substrate turnover
The 26S proteasome typically degrades proteins marked by ubiquitin chains. However, a distinct, ubiquitin-independent degradation pathway for nuclear proteins exists, mediated by the adaptor protein midnolin, yet its molecular mechanism remains poorly understood. Here, we present nine cryo-electron microscopy structures of the human 26S proteasome in complex with midnolin, which collectively delineate a near-complete catalytic cycle. Our structures reveal that midnolin binds to the proteasome via the RPN1 subunit by its C-terminal helix. Unexpectedly, its ubiquitin-like domain interacts with the RPN11 deubiquitinase in a non-catalytic role. This interaction positions the adjacent Catch domain, which is responsible for substrate binding, directly above the proteasomal entrance, potentially facilitating substrate entry into the proteasome. Furthermore, we observe four consecutive spiral staircase conformations of the AAA+ ATPase hexamer during substrate translocation. These findings provide insights into the mechanisms underlying ubiquitin-independent nuclear protein degradation and may help develop strategies for targeting nuclear proteins via direct proteasomal degradation.
- 27 March 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 2800
Open AccessStructural dynamics of the midnolin-proteasome during ubiquitin-independent substrate turnover
The 26S proteasome typically degrades proteins marked by ubiquitin chains. However, a distinct, ubiquitin-independent degradation pathway for nuclear proteins exists, mediated by the adaptor protein midnolin, yet its molecular mechanism remains poorly understood. Here, we present nine cryo-electron microscopy structures of the human 26S proteasome in complex with midnolin, which collectively delineate a near-complete catalytic cycle. Our structures reveal that midnolin binds to the proteasome via the RPN1 subunit by its C-terminal helix. Unexpectedly, its ubiquitin-like domain interacts with the RPN11 deubiquitinase in a non-catalytic role. This interaction positions the adjacent Catch domain, which is responsible for substrate binding, directly above the proteasomal entrance, potentially facilitating substrate entry into the proteasome. Furthermore, we observe four consecutive spiral staircase conformations of the AAA+ ATPase hexamer during substrate translocation. These findings provide insights into the mechanisms underlying ubiquitin-independent nuclear protein degradation and may help develop strategies for targeting nuclear proteins via direct proteasomal degradation.
- Open Access
- 1 January 2026
- Published by KEAI Publishing in Bioactive Materials
- Vol. 55, 658-678
Learn from nature: Biomimetic nanocarriers for intracellular protein delivery
Nanocarriers have been regarded as the most potential therapeutic weapons to combat tumors and genetic diseases using protein drugs. However, nanocarriers often face many challenges during the delivery process. Due to the existence of cell membrane barriers, nanocarriers may be restricted extracellularly or degraded in lysosomes, thus unable to effectively deliver drugs to the target location. The biomimetic nanocarrier delivery systems have demonstrated unique advantages in the field of protein delivery. This review focuses on cutting-edge technologies such as biomimetic mineralized nanoparticles, Virus-like particles, and bacterium-like nanoparticles. These biomimetic nanocarriers exhibit great potential to bypass endocytosis and lysosomal restrictions due to their unique biomimetic properties. Additionally, this review reviews the latest progress of cytosolic protein drug delivery systems based on biomimetic systems in various medical research and clinical applications, including clinical targeted delivery, tumor therapy, and gene editing. It also compares the capabilities and limitations of these biomimetic cytosolic protein delivery systems with traditional nanocarriers, including factors that affect protein delivery efficiency, and emphasizes their potential to adopt targeted, sustainable, and minimally invasive treatment methods. Finally, this review proposes the current limitations and future research directions of protein delivery systems, expecting to provide more efficient solutions for disease treatment.
- 1 January 2026
- Published by KEAI Publishing in Bioactive Materials
- Vol. 55, 658-678
Open AccessLearn from nature: Biomimetic nanocarriers for intracellular protein delivery
Nanocarriers have been regarded as the most potential therapeutic weapons to combat tumors and genetic diseases using protein drugs. However, nanocarriers often face many challenges during the delivery process. Due to the existence of cell membrane barriers, nanocarriers may be restricted extracellularly or degraded in lysosomes, thus unable to effectively deliver drugs to the target location. The biomimetic nanocarrier delivery systems have demonstrated unique advantages in the field of protein delivery. This review focuses on cutting-edge technologies such as biomimetic mineralized nanoparticles, Virus-like particles, and bacterium-like nanoparticles. These biomimetic nanocarriers exhibit great potential to bypass endocytosis and lysosomal restrictions due to their unique biomimetic properties. Additionally, this review reviews the latest progress of cytosolic protein drug delivery systems based on biomimetic systems in various medical research and clinical applications, including clinical targeted delivery, tumor therapy, and gene editing. It also compares the capabilities and limitations of these biomimetic cytosolic protein delivery systems with traditional nanocarriers, including factors that affect protein delivery efficiency, and emphasizes their potential to adopt targeted, sustainable, and minimally invasive treatment methods. Finally, this review proposes the current limitations and future research directions of protein delivery systems, expecting to provide more efficient solutions for disease treatment.
- Open Access
- 27 November 2025
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 23 (1)
Photocurable hydrogel containing MOF nanoenzymes for comprehensive pulpitis treatment: antibacterial, anti-inflammatory, and osteogenic actions
Maintaining the vitality of the dental pulp tissue is the core therapeutic objective in treating reversible pulpitis, with the key being the achievement of
- 27 November 2025
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 23 (1)
Open AccessPhotocurable hydrogel containing MOF nanoenzymes for comprehensive pulpitis treatment: antibacterial, anti-inflammatory, and osteogenic actions
Maintaining the vitality of the dental pulp tissue is the core therapeutic objective in treating reversible pulpitis, with the key being the achievement of
- 3 July 2025
- Published by Wiley in Advanced Materials
- Vol. 37 (42) , e2419870
Engineering a Lipid Nanoparticle with Atypical Calcium Crystal Structure for Enhanced IFNβ‐Mediated Immunotherapy
Immune checkpoint inhibitors have revolutionized cancer therapy; however, many patients exhibit suboptimal responses, which is due to inadequate T cell priming by the innate immune response. Metal ions play a critical role in modulating the innate immune response. However, the mechanisms by which metal ions facilitate dendritic cell maturation through the activation of interferon remain poorly understood. This research identifies a nanomaterial Calcium phosphate‐containing liposome (NanoCa), characterized by an atypical crystal structure and pH‐responsive profile. NanoCa promotes bone marrow‐derived dendritic cell maturation and exhibits antiviral effects and anti‐tumor properties in different tumor models. Also, NanoCa acts as an immunostimulant by fostering antibody production. Furthermore, when combined with programmed cell death 1 receptor (PD‐1) blocking antibodies, NanoCa synergistically enhances anti‐tumor efficacy in CT26 models. Mechanistically, NanoCa rapidly releases Ca 2+ via the lysosome pathway post‐endocytosis, subsequently triggering interferon through the Ca 2+ ‐calcineurin (CaN) ‐ nuclear factor of activated T cells 2 (NFATc2) ‐ protein kinase C beta (PKCβ) ‐ interferon regulatory factor 3 (IRF3) signal pathway. Single‐cell RNA sequencing (scRNA‐seq) shows NanoCa increases the population of tumoral infiltrating dendritic cell (DC), C1qc+ TAM, and CD8T_eff cells and decreases the CD8T_ex and immunosuppressive SPP1+ TAM population in tumor‐draining lymph nodes. Overall, NanoCa shows translational potential for anti‐tumor immune therapeutics.
- 3 July 2025
- Published by Wiley in Advanced Materials
- Vol. 37 (42) , e2419870
Engineering a Lipid Nanoparticle with Atypical Calcium Crystal Structure for Enhanced IFNβ‐Mediated Immunotherapy
Immune checkpoint inhibitors have revolutionized cancer therapy; however, many patients exhibit suboptimal responses, which is due to inadequate T cell priming by the innate immune response. Metal ions play a critical role in modulating the innate immune response. However, the mechanisms by which metal ions facilitate dendritic cell maturation through the activation of interferon remain poorly understood. This research identifies a nanomaterial Calcium phosphate‐containing liposome (NanoCa), characterized by an atypical crystal structure and pH‐responsive profile. NanoCa promotes bone marrow‐derived dendritic cell maturation and exhibits antiviral effects and anti‐tumor properties in different tumor models. Also, NanoCa acts as an immunostimulant by fostering antibody production. Furthermore, when combined with programmed cell death 1 receptor (PD‐1) blocking antibodies, NanoCa synergistically enhances anti‐tumor efficacy in CT26 models. Mechanistically, NanoCa rapidly releases Ca 2+ via the lysosome pathway post‐endocytosis, subsequently triggering interferon through the Ca 2+ ‐calcineurin (CaN) ‐ nuclear factor of activated T cells 2 (NFATc2) ‐ protein kinase C beta (PKCβ) ‐ interferon regulatory factor 3 (IRF3) signal pathway. Single‐cell RNA sequencing (scRNA‐seq) shows NanoCa increases the population of tumoral infiltrating dendritic cell (DC), C1qc+ TAM, and CD8T_eff cells and decreases the CD8T_ex and immunosuppressive SPP1+ TAM population in tumor‐draining lymph nodes. Overall, NanoCa shows translational potential for anti‐tumor immune therapeutics.
- Top Cited PapersOpen Access
- 9 March 2025
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 23 (1) , 1-18
Recent advances and challenges in metal-based antimicrobial materials: a review of strategies to combat antibiotic resistance
Despite the availability of a series of classical antibiotic drugs, bacterial infections continue to represent a significant and urgent threat to global human health. The emergence of drug-resistant bacteria and the slow pace of antibiotic development have rendered current treatment methods inadequate in meeting the clinical demands of bacterial infections. Consequently, there is an increasingly urgent and vital need for the development of safe, efficient, and alternative novel antimicrobial agents in the medical and healthcare field. Over the past five years, there has been a notable expansion in the field of nanomedicine with regard to the prevention and control of infectious diseases. The objective of this article is to provide a comprehensive review of the latest research developments in the field of metal nanomaterials for medical antimicrobial therapy. We begin by delineating the gravity of the bacterial infection crisis, subsequently undertaking a comprehensive examination of the potential mechanisms through which nanoparticles may combat bacterial infections and the specific applications of these nanomaterials in the treatment of diverse infectious diseases. In conclusion, we eagerly anticipate the future development directions of metal nanomaterials in the field of antimicrobial therapy. We believe that with continuous technological advancements and innovations, this field will make even more outstanding contributions to safeguarding human health and well-being.
- 9 March 2025
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 23 (1) , 1-18
Top Cited PapersOpen AccessRecent advances and challenges in metal-based antimicrobial materials: a review of strategies to combat antibiotic resistance
Despite the availability of a series of classical antibiotic drugs, bacterial infections continue to represent a significant and urgent threat to global human health. The emergence of drug-resistant bacteria and the slow pace of antibiotic development have rendered current treatment methods inadequate in meeting the clinical demands of bacterial infections. Consequently, there is an increasingly urgent and vital need for the development of safe, efficient, and alternative novel antimicrobial agents in the medical and healthcare field. Over the past five years, there has been a notable expansion in the field of nanomedicine with regard to the prevention and control of infectious diseases. The objective of this article is to provide a comprehensive review of the latest research developments in the field of metal nanomaterials for medical antimicrobial therapy. We begin by delineating the gravity of the bacterial infection crisis, subsequently undertaking a comprehensive examination of the potential mechanisms through which nanoparticles may combat bacterial infections and the specific applications of these nanomaterials in the treatment of diverse infectious diseases. In conclusion, we eagerly anticipate the future development directions of metal nanomaterials in the field of antimicrobial therapy. We believe that with continuous technological advancements and innovations, this field will make even more outstanding contributions to safeguarding human health and well-being.
- Open Access
- 19 April 2024
- Published by MDPI AG in Pharmaceutics
- Vol. 16 (4) , 556
High Manganese Content of Lipid NanoMn (LNM) by Microfluidic Technology for Enhancing Anti-Tumor Immunity
Immunotherapy is a clinically effective method for treating tumors. Manganese can activate the cGAS-STING signaling pathway and induce an anti-tumor immune response. However, its efficacy is hindered by non-specific distribution and low uptake rates. In this study, we employed microfluidic technology to design and develop an innovative preparation process, resulting in the creation of a novel manganese lipid nanoparticle (LNM). The lipid manganese nanoparticle produced in this process boasts a high manganese payload, excellent stability, the capacity for large-scale production, and high batch repeatability. LNM has effectively demonstrated the ability to activate the cGAS-STING signaling pathway, induce the production of pro-inflammatory cytokines, and inhibit tumor development. Notably, LNM does not require combination chemotherapy drugs or other immune activators. Therefore, LNM presents a safe, straightforward, and efficient strategy for anti-tumor immune activation, with the potential for scalable production.
- 19 April 2024
- Published by MDPI AG in Pharmaceutics
- Vol. 16 (4) , 556
Open AccessHigh Manganese Content of Lipid NanoMn (LNM) by Microfluidic Technology for Enhancing Anti-Tumor Immunity
Immunotherapy is a clinically effective method for treating tumors. Manganese can activate the cGAS-STING signaling pathway and induce an anti-tumor immune response. However, its efficacy is hindered by non-specific distribution and low uptake rates. In this study, we employed microfluidic technology to design and develop an innovative preparation process, resulting in the creation of a novel manganese lipid nanoparticle (LNM). The lipid manganese nanoparticle produced in this process boasts a high manganese payload, excellent stability, the capacity for large-scale production, and high batch repeatability. LNM has effectively demonstrated the ability to activate the cGAS-STING signaling pathway, induce the production of pro-inflammatory cytokines, and inhibit tumor development. Notably, LNM does not require combination chemotherapy drugs or other immune activators. Therefore, LNM presents a safe, straightforward, and efficient strategy for anti-tumor immune activation, with the potential for scalable production.
- 21 February 2024
- Published by Elsevier in Chemical Engineering Journal
- Vol. 485
An elastase nanocomplex with metal cofactors for enhancement of target protein cleavage activity and synergistic antitumor effect
- 21 February 2024
- Published by Elsevier in Chemical Engineering Journal
- Vol. 485
An elastase nanocomplex with metal cofactors for enhancement of target protein cleavage activity and synergistic antitumor effect
- 10 August 2023
- Published by Royal Society of Chemistry (RSC) in Nanoscale
- Vol. 15 (34) , 13971-13986
Engineering core–shell chromium nanozymes with inflammation-suppressing, ROS-scavenging and antibacterial properties for pulpitis treatment
NanoCr has optimal biocompatibility, antibacterial and anti-inflammatory properties inin vitrocell models and could be a promising material for pulp repair and an effective strategy for the treatment of pulpitis.
- 10 August 2023
- Published by Royal Society of Chemistry (RSC) in Nanoscale
- Vol. 15 (34) , 13971-13986
Engineering core–shell chromium nanozymes with inflammation-suppressing, ROS-scavenging and antibacterial properties for pulpitis treatment
NanoCr has optimal biocompatibility, antibacterial and anti-inflammatory properties inin vitrocell models and could be a promising material for pulp repair and an effective strategy for the treatment of pulpitis.